Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30967332 | 0.78 | MAPT (0.38) | — | |
| SCHEMBL22283892 | 0.73 | DYRK1A (0.39) | ADORA3RECQLCYP1A2KMO | |
| SCHEMBL29792823 | 0.73 | DYRK1A (0.39) | ADORA3RECQLCYP1A2KMO | |
| SCHEMBL515578 | 0.71 | CA12 (0.34) | RECQLMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL21268466 | 0.69 | SLC9A1 (0.42) | ADORA3KMT2ACYP1A2KDM4EPOLB | |
| SCHEMBL29354440 | 0.68 | SMN1; SMN2 (0.39) | ADORA3RECQLKMT2ACYP1A2KDM4E | |
| SCHEMBL4510784 | 0.68 | SMN1; SMN2 (0.39) | ADORA3RECQLKMT2ACYP1A2KDM4E | |
| SCHEMBL5656535 | 0.68 | KMT2A (0.44) | MEN1KMT2AKDM4EPOLBMAPK1 | |
| SCHEMBL29881244 | 0.67 | NPSR1 (0.47) | ADORA3MEN1KMT2AKDM4EPOLB | |
| SCHEMBL10666827 | 0.66 | KDM4E (0.40) | RECQLMEN1KMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0745154-B1 | MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM | LIGNOZYM GMBH (DE) | 1998-09-16 | — | — | EP | claimed |
| EP-0085840-B1 | NEW 6-SUBSTITUTED-S-TRIAZOLO(3,4-A)PHTHALAZINE DERIVATIVES | GRUPPO LEPETIT S.P.A. (IT) | 1986-10-01 | — | — | EP | claimed |
| EP-0085840-A1 | New 6-substituted-s-triazolo(3,4-a)phthalazine derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1983-08-17 | — | — | EP | claimed |
| EP-3153498-B1 | N-SUBSTITUTED PHENYL GLYCINE PREPARATION METHOD | ABA CHEMICALS CORP (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-7144887-B2 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2006-12-05 | — | — | US | disclosed |
| US-7144887-B2 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20030125333-A1 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2003-07-03 | — | — | US | disclosed |
| US-6310203-B1 | Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands | MERCK SHARPE & DOHME LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| WO-2001044250-A1 | SUBSTITUTED 1,2,3-TRIAZOLO[1,5-a]QUINAZOLINES FOR ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| EP-0845026-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL, Hans-Peter Dr. (DE) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997048786-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL HANS PETER (DE) | 1997-12-24 | — | — | WO | disclosed |
| US-5084007-A | Method for chemical promotion of the effects of low current transcranial electrostimulation | MALIN DAVID H (US) | 1992-01-28 | — | — | US | disclosed |
| US-4788186-A | ANXIOLYTIC AGENTS | GRUPPO LEPETIT S.P.A. (IT) | 1988-11-29 | — | — | US | disclosed |
| US-4783461-A | ANXIOLYTIC AGENTS | GRUPPO LEPETIT S.P.A. (IT) | 1988-11-08 | — | — | US | disclosed |
| EP-0134946-B1 | 3,6-Disubstituted-triazolo[3,4-a]phthalazine derivatives | GRUPPO LEPETIT S.p.A. (IT) | 1987-08-12 | — | — | EP | disclosed |
| EP-0085840-B1 | NEW 6-SUBSTITUTED-S-TRIAZOLO(3,4-A)PHTHALAZINE DERIVATIVES | GRUPPO LEPETIT S.P.A. (IT) | 1986-10-01 | — | — | EP | disclosed |
| EP-0134946-A1 | 3,6-Disubstituted-triazolo[3,4-a]phthalazine derivatives | GRUPPO LEPETIT S.p.A. (IT) | 1985-03-27 | — | — | EP | disclosed |
| EP-0085840-A1 | New 6-substituted-s-triazolo(3,4-a)phthalazine derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125333-A1 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | HAX1, HTR1D, CHRM1 | ADORA3 120/4885RECQL 211/4885MEN1 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.